FW1256
|
|
|
- CAS號:
- 117089-08-4
- 英文名:
- FW1256
- 英文別名:
- FW1256;FW1256,FW-1256;1,3,2-Benzoxazaphosphole, 2,3-dihydro-2-phenyl-, 2-sulfide
- 中文名:
- FW1256
- 中文別名:
- 化合物 T15361
- CBNumber:
- CB23335176
- 分子式:
- C12H10NOPS
- 分子量:
- 247.25
- MOL File:
- 117089-08-4.mol
|
|
|
FW1256化學性質
-
熔點:
-
139-142 °C
-
|
-
沸點:
-
376.3±25.0 °C(Predicted)
-
|
-
密度:
-
1.37±0.1 g/cm3(Predicted)
-
|
-
儲存條件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: ≥ 250 mg/mL (1011.12 mM)
-
|
-
酸度系數(shù)(pKa):
-
-0.88±0.20(Predicted)
-
|
-
形態(tài):
-
Solid
-
|
-
顏色:
-
White to off-white
-
|
FW1256性質、用途與生產(chǎn)工藝
FW1256 是一種苯基類似物，也是一種緩釋硫化氫 (H2S) 供體。FW1256 抑制 NF-κB 活性，并可誘導細胞凋亡 (apoptosis)，具有有效的抗炎作用，并可用于癌癥和心血管疾病的研究。
FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages.
FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS PROTE and protein in LPS-stimulated RAW264.7 macrophages.
FW1256 concentration dependently decreases TNF-α (IC
50
of 61.2 μM), IL-6 (IC
50
of 11.7 μM), PGE2 (IC
50
of 25.5 μM) and NO (IC
50
of 34.6 μM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC
50
s of 414.9 μM, 300.2 μM, 4 μM and 9.5 μM for TNF-α, IL-6, PGE2 and NO, respectively) .
FW1256 decreases NF-κB activation as evidenced by reduced cytosolic phospho-IκBα levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256.
RT-PCR
|
Cell Line:
|
RAW264.7 cells
|
|
Concentration:
|
200 μM
|
|
Incubation Time:
|
24.5 hours
|
|
Result:
|
Significantly reduced IL-1β, COX-2 and iNOS mRNA in LPS-stimulated RAW264.7 macrophages..
|
Western Blot Analysis
|
Cell Line:
|
RAW264.7 cells
|
|
Concentration:
|
200 μM
|
|
Incubation Time:
|
24.5 hours
|
|
Result:
|
Significantly reduced IL-1β, COX-2 and iNOS proteinin LPS-stimulated RAW264.7 macrophages..
|
FW1256 (100 mg/kg; intraperitoneal injection; male C57BL/6 mice) treatment reduces IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.
|
Animal Model:
|
Male C57BL/6 mice (20-25 g, 6-10 weeks) injected with
E. coli
lipopolysaccharide (LPS)
|
|
Dosage:
|
100 mg/kg
|
|
Administration:
|
Intraperitoneal injection
|
|
Result:
|
Reduced IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.
|
FW1256
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2024/11/08 | HY-121955 | FW1256 | | 1 mg | 1280元 |
| 2024/11/08 | HY-121955 | FW1256
FW1256 | 117089-08-4 | 5mg | 3200元 |
117089-08-4, FW1256 相關搜索:
- C12H10NOPS
- 化合物 T15361
- 117089-08-4
- FW1256,FW-1256
- 1,3,2-Benzoxazaphosphole, 2,3-dihydro-2-phenyl-, 2-sulfide
- FW1256